Patents by Inventor Daniel Walz

Daniel Walz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10813985
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: April 20, 2020
    Date of Patent: October 27, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
  • Publication number: 20200325174
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: June 24, 2020
    Publication date: October 15, 2020
    Inventors: Juliane WALZ, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC
  • Patent number: 10799571
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: April 30, 2020
    Date of Patent: October 13, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
  • Publication number: 20200308226
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Hans-Georg RAMMENSEE, Juliane WALZ, Daniel Johannes KOWALEWSKI, Stefan STEVANOVIC, Simon WALZ
  • Publication number: 20200308225
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Hans-Georg RAMMENSEE, Juliane WALZ, Daniel Johannes KOWALEWSKI, Stefan STEVANOVIC, Simon WALZ
  • Publication number: 20200308227
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: June 16, 2020
    Publication date: October 1, 2020
    Inventors: Hans-Georg RAMMENSEE, Juliane WALZ, Daniel Johannes KOWALEWSKI, Stefan STEVANOVIC, Simon WALZ
  • Patent number: 10781233
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: May 29, 2019
    Date of Patent: September 22, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Juliane Walz, Daniel Johannes Kowalewski, Stefan Stevanovic, Simon Walz
  • Publication number: 20200268862
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: April 20, 2020
    Publication date: August 27, 2020
    Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
  • Publication number: 20200254078
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
  • Patent number: 10730910
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 4, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Patent number: 10668137
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: June 2, 2020
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
  • Publication number: 20200157148
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: January 24, 2020
    Publication date: May 21, 2020
    Inventors: Juliane WALZ, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC
  • Publication number: 20200093905
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: December 5, 2019
    Publication date: March 26, 2020
    Inventors: Hans-Georg RAMMENSEE, Stefan STEVANOVIC, Juliane WALZ, Daniel Johannes KOWALEWSKI, Claudia BERLIN
  • Patent number: 10570175
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: February 25, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Patent number: 10525115
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: March 29, 2019
    Date of Patent: January 7, 2020
    Assignee: Immatics Biotechnologies GmbH
    Inventors: Hans-Georg Rammensee, Stefan Stevanovic, Juliane Walz, Daniel Johannes Kowalewski, Claudia Berlin
  • Patent number: 10464007
    Abstract: A filter cartridge for a filter apparatus, including: a filter element that encloses an clean space within the filter element, at least partially; wherein the filter element has an outflow opening in flow communication with the clean space in the filter element; wherein the filter element has a longitudinal axis extending through the filter element and through the outflow opening; wherein a hollow base for connecting to a housing-side fastening element is arranged on or in the clean space; wherein an interior of the hollow base is sealed off from the clean space in a flow-tight manner.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 5, 2019
    Assignee: MANN+HUMMEL GmbH
    Inventors: Frank Pflueger, Fabian Wagner, Matthias Krohlow, Daniel Schmid, Joerg Menssen, Stefan Walz, Christof Mangold
  • Patent number: 10450346
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Grant
    Filed: May 24, 2019
    Date of Patent: October 22, 2019
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
  • Patent number: 10443503
    Abstract: A gas turbine fuel system including a main fuel line providing fuel flow from a fuel tank to a combustor, and at least one pump, including an ejector pump, pumping fuel from the fuel tank to the combustor via a fuel metering unit. The fuel metering unit directs a portion of the fuel into a motive flow line which returns a portion of the fuel to the ejector pump. First and second heat exchangers are disposed in serial flow communication within the main fuel line between the pump and the fuel metering unit. The first heat exchanger is a fuel-to-fuel heat exchanger.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: October 15, 2019
    Assignee: PRATT & WHITNEY CANADA CORP.
    Inventors: Daniel Alecu, Steven Strecker, Andrew Walz
  • Publication number: 20190284235
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular myeloma. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Application
    Filed: May 29, 2019
    Publication date: September 19, 2019
    Inventors: Hans-Georg RAMMENSEE, Juliane WALZ, Daniel Johannes KOWALEWSKI, Stefan STEVANOVIC, Simon WALZ
  • Publication number: 20190284233
    Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
    Type: Application
    Filed: May 24, 2019
    Publication date: September 19, 2019
    Inventors: Juliane WALZ, Daniel Johannes KOWALEWSKI, Hans-Georg RAMMENSEE, Stefan STEVANOVIC